Serum apolipoprotein A1 and B are associated with 6-month persistent and incident diabetic macular oedema in type 2 diabetes
Aims To investigate the associations of baseline apolipoprotein A1 (ApoA1) and B (ApoB) levels with persistent and incident diabetic macular oedema (DMO) after 6 months of follow-up.Methods This is a prospective cohort study of patients aged ≥30 years with untreated diabetic retinopathy. Examination...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-06-01
|
| Series: | BMJ Open Ophthalmology |
| Online Access: | https://bmjophth.bmj.com/content/8/1/e001207.full |
| _version_ | 1827147707470315520 |
|---|---|
| author | Muhammad Bayu Sasongko Madarina Julia Soefiandi Soedarman Tjahjono D Gondhowiardjo Alberthus Donni Budi Prasetya King Hans Kurnia |
| author_facet | Muhammad Bayu Sasongko Madarina Julia Soefiandi Soedarman Tjahjono D Gondhowiardjo Alberthus Donni Budi Prasetya King Hans Kurnia |
| author_sort | Muhammad Bayu Sasongko |
| collection | DOAJ |
| description | Aims To investigate the associations of baseline apolipoprotein A1 (ApoA1) and B (ApoB) levels with persistent and incident diabetic macular oedema (DMO) after 6 months of follow-up.Methods This is a prospective cohort study of patients aged ≥30 years with untreated diabetic retinopathy. Examinations, fundus photography and spectral domain optical coherence tomography (SD-OCT) were assessed at baseline, 1, 3 and 6 months. Serum lipids and apolipoproteins were analysed at a pathology laboratory. DMO was confirmed using SD-OCT, classified as (1) incident DMO, (2) persistent DMO and (3) regressed DMO. Eye-specific data were used, controlling for covariates and cluster effect.Results We recruited 53 patients but only 38 completed the study [(62 eyes), 20 eyes (32.3%) with DMO]. Higher quartile of ApoA1 was associated with lower risk of persistent/incident DMO (p for trend 0.02), while higher ApoB/A1 was associated with higher risk of persistent/incident DMO (p for trend 0.02). Every 10 mg/dL increase in ApoA1 levels was associated with lower risk of persistent/incident DMO (OR 0.69; 95% CI 0.49 to 0.92; p value 0.016), whereas every 0.2 increase in ApoB/A1 was significantly associated with higher risk of persistent/incident DMO (OR 1.4; 95% CI 1.1 to 1.9; p value 0.013) at the end of the study.Conclusion Individuals with diabetes with higher ApoA1 had lower risk of persistent/incident DMO and those with higher ApoB/A1 had higher risk of persistent/incident DMO at the end of 6 months. These suggest that serum ApoA1 and ApoB/A1 levels may be important risk factors for DMO and could be predictive of persistent/incident DMO despite anti-vascular endothelial growth factor treatment. |
| first_indexed | 2024-03-08T17:23:18Z |
| format | Article |
| id | doaj.art-feaefa71abfa4ad19abef27716a54930 |
| institution | Directory Open Access Journal |
| issn | 2397-3269 |
| language | English |
| last_indexed | 2025-03-20T20:50:40Z |
| publishDate | 2023-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open Ophthalmology |
| spelling | doaj.art-feaefa71abfa4ad19abef27716a549302024-08-14T12:50:11ZengBMJ Publishing GroupBMJ Open Ophthalmology2397-32692023-06-018110.1136/bmjophth-2022-001207Serum apolipoprotein A1 and B are associated with 6-month persistent and incident diabetic macular oedema in type 2 diabetesMuhammad Bayu Sasongko0Madarina Julia1Soefiandi Soedarman2Tjahjono D Gondhowiardjo3Alberthus Donni Budi Prasetya4King Hans Kurnia5Department of Ophthalmology, Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada - Sardjito Eye Center, Dr. Sardjito General Hospital, Yogyakarta, IndonesiaDepartment of Child Health, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, IndonesiaJEC Eye Hospitals & Clinics, Jakarta, IndonesiaJEC Eye Hospitals & Clinics, Jakarta, IndonesiaJEC Eye Hospitals & Clinics, Jakarta, IndonesiaJEC Eye Hospitals & Clinics, Jakarta, IndonesiaAims To investigate the associations of baseline apolipoprotein A1 (ApoA1) and B (ApoB) levels with persistent and incident diabetic macular oedema (DMO) after 6 months of follow-up.Methods This is a prospective cohort study of patients aged ≥30 years with untreated diabetic retinopathy. Examinations, fundus photography and spectral domain optical coherence tomography (SD-OCT) were assessed at baseline, 1, 3 and 6 months. Serum lipids and apolipoproteins were analysed at a pathology laboratory. DMO was confirmed using SD-OCT, classified as (1) incident DMO, (2) persistent DMO and (3) regressed DMO. Eye-specific data were used, controlling for covariates and cluster effect.Results We recruited 53 patients but only 38 completed the study [(62 eyes), 20 eyes (32.3%) with DMO]. Higher quartile of ApoA1 was associated with lower risk of persistent/incident DMO (p for trend 0.02), while higher ApoB/A1 was associated with higher risk of persistent/incident DMO (p for trend 0.02). Every 10 mg/dL increase in ApoA1 levels was associated with lower risk of persistent/incident DMO (OR 0.69; 95% CI 0.49 to 0.92; p value 0.016), whereas every 0.2 increase in ApoB/A1 was significantly associated with higher risk of persistent/incident DMO (OR 1.4; 95% CI 1.1 to 1.9; p value 0.013) at the end of the study.Conclusion Individuals with diabetes with higher ApoA1 had lower risk of persistent/incident DMO and those with higher ApoB/A1 had higher risk of persistent/incident DMO at the end of 6 months. These suggest that serum ApoA1 and ApoB/A1 levels may be important risk factors for DMO and could be predictive of persistent/incident DMO despite anti-vascular endothelial growth factor treatment.https://bmjophth.bmj.com/content/8/1/e001207.full |
| spellingShingle | Muhammad Bayu Sasongko Madarina Julia Soefiandi Soedarman Tjahjono D Gondhowiardjo Alberthus Donni Budi Prasetya King Hans Kurnia Serum apolipoprotein A1 and B are associated with 6-month persistent and incident diabetic macular oedema in type 2 diabetes BMJ Open Ophthalmology |
| title | Serum apolipoprotein A1 and B are associated with 6-month persistent and incident diabetic macular oedema in type 2 diabetes |
| title_full | Serum apolipoprotein A1 and B are associated with 6-month persistent and incident diabetic macular oedema in type 2 diabetes |
| title_fullStr | Serum apolipoprotein A1 and B are associated with 6-month persistent and incident diabetic macular oedema in type 2 diabetes |
| title_full_unstemmed | Serum apolipoprotein A1 and B are associated with 6-month persistent and incident diabetic macular oedema in type 2 diabetes |
| title_short | Serum apolipoprotein A1 and B are associated with 6-month persistent and incident diabetic macular oedema in type 2 diabetes |
| title_sort | serum apolipoprotein a1 and b are associated with 6 month persistent and incident diabetic macular oedema in type 2 diabetes |
| url | https://bmjophth.bmj.com/content/8/1/e001207.full |
| work_keys_str_mv | AT muhammadbayusasongko serumapolipoproteina1andbareassociatedwith6monthpersistentandincidentdiabeticmacularoedemaintype2diabetes AT madarinajulia serumapolipoproteina1andbareassociatedwith6monthpersistentandincidentdiabeticmacularoedemaintype2diabetes AT soefiandisoedarman serumapolipoproteina1andbareassociatedwith6monthpersistentandincidentdiabeticmacularoedemaintype2diabetes AT tjahjonodgondhowiardjo serumapolipoproteina1andbareassociatedwith6monthpersistentandincidentdiabeticmacularoedemaintype2diabetes AT alberthusdonnibudiprasetya serumapolipoproteina1andbareassociatedwith6monthpersistentandincidentdiabeticmacularoedemaintype2diabetes AT kinghanskurnia serumapolipoproteina1andbareassociatedwith6monthpersistentandincidentdiabeticmacularoedemaintype2diabetes |